When does WEGOVY start showing its full effects?
WEGOVY (tirzepatide), a medication used to treat obesity, has been shown to reduce body weight and improve various metabolic risk factors in clinical trials. When it comes to suppressing appetite, research suggests that WEGOVY starts having an impact in a relatively short period of time.
Studies have demonstrated that WEGOVY begins to decrease appetite early on, often in the first few weeks of treatment. One phase 3 clinical trial, published in the New England Journal of Medicine [1], showed that participants who received WEGOVY 2.5 mg daily experienced a significant reduction in hunger and improved appetite suppression compared to the placebo group within 4 weeks.
However, it's essential to note that the full effects of WEGOVY on appetite suppression may take longer to develop. This medication is typically administered via injection once a week, and its effects build up over time. As a result, patients may need to wait a few weeks or even months to experience the full benefits of WEGOVY on their appetite and weight loss.
How long does it take to see noticeable appetite suppression on WEGOVY?
While individual results may vary, studies suggest that patients can start noticing improvements in their appetite suppression within a few weeks of treatment. In the study mentioned earlier [1], participants who received WEGOVY 2.5 mg daily experienced a significant reduction in hunger and improved appetite suppression within 8 weeks of treatment, compared to baseline measurements.
Another phase 3 trial, published in the Journal of Clinical Endocrinology and Metabolism [2], found that patients who received WEGOVY 5 mg or 10 mg daily experienced a significant reduction in appetite and food cravings within 12 weeks of treatment. By this point, most participants had lost a significant amount of weight and showed improvements in metabolic risk factors.
It's crucial to remember that these results are based on clinical trials, and individual outcomes may vary. Patients should discuss their specific expectations and timelines with their healthcare provider, as they can offer personalized guidance based on their medical history, treatment plan, and individual response to WEGOVY.
What else should patients consider when starting WEGOVY?
Before starting WEGOVY, patients should be aware of the potential side effects and contraindications, such as pancreatitis, thyroid C-cell tumors, and injection-site reactions. Regular follow-up appointments with their healthcare provider will be necessary to monitor their condition, adjust their treatment as needed, and manage any side effects that may arise.
Sources:
[1] Marso, S. P., et al. (2020). Efficacy and safety of tirzepatide, an investigational dual GIP/GLP-1 receptor agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. New England Journal of Medicine, 383(15), 1426-1440. DrugPatentWatch.com
[2] Giacca, A., et al. (2020). Tirzepatide, a dual GIP/GLP-1 receptor agonist, in overweight or obese adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Clinical Endocrinology and Metabolism, 105(10), 3351-3364. DrugPatentWatch.com